Rhythm Biosciences Limited
AASX:RHY0.07
AUD
0.00
(0.00%)
ISIN
AU000000RHY2
Return %
Stock
S&P 500
1Y
-29.47
14.20
3Y
-59.74
81.12
5Y
-94.97
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- David George Atkins
- Full Time Employees
- 23
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Bio21 Institute Parkville VIC Australia 3010
- IPO Date
- Dec 7, 2017
- Website
- rhythmbio.com
- Similar Companies
- Business
- Rhythm Biosciences Limited (ASX:RHY) develops and commercializes innovative blood-based diagnostic tests for early cancer detection and genetic risk assessment, primarily targeting colorectal cancer and multiple other cancer types; its flagship ColoSTAT test-kit measures five specific protein biomarkers to detect colorectal cancer as a non-invasive alternative to traditional screening; the geneType platform delivers personalized polygenic risk scores (PRS) for cancers including breast, colorectal, ovarian, pancreatic, prostate, melanoma, and coronary artery disease, atrial fibrillation, and type II diabetes, using genomic and clinical data from saliva or buccal swabs; additional offerings encompass molecular genetics services such as DNA extraction, predictive genetic testing, and bioinformatic analysis for primary, secondary, and tertiary data processing. The company, founded in 2017 and headquartered at the Bio21 Institute in Parkville, Melbourne, Australia, operates in Australia and the United States, serving healthcare systems, clinicians, and at-risk populations to reduce cancer burden through accessible screening solutions. In December 2024, Rhythm completed the acquisition of the geneType business and assets from Genetic Technologies Limited for approximately A$0.625 million, integrating its commercial genomic risk assessment portfolio to create synergies with ColoSTAT, generate immediate revenue, diversify capabilities, and expand the U.S. footprint with key personnel transfers; subsequent integration commenced with transitional support, funded by R&D tax incentives; in August 2025, the company finalized validation of its second-generation ColoSTAT multiplex alpha kit and submitted for NATA accreditation, alongside board renewals including CEO David Atkins' expanded role and new director appointments in late 2024.